A recent review has sparked a fascinating debate: Can psychedelics offer hope for those battling Obsessive-Compulsive Disorder (OCD), while cannabis falls short?
Dr. Michael Van Ameringen, a psychiatry professor, led a study published in the Journal of Psychiatric Research, diving into alternative treatments for OCD. The findings? Psychedelics are showing promise, but cannabis isn't following suit. This is crucial because a significant 40-60% of OCD patients find little to no relief from existing treatments, like SSRIs and exposure therapy.
While both psychedelics and cannabinoids have entered the conversation around OCD, characterized by intrusive thoughts and compulsive behaviors, the evidence supporting their effectiveness for more common conditions like depression and anxiety is more established. Van Ameringen aimed to understand if these substances could be the next step in treatment.
Given the limited research, Van Ameringen included conference presentations and unpublished findings. The results revealed "stronger signals" for psychedelics, particularly psilocybin (the active compound in magic mushrooms), compared to cannabinoids like THC and CBD. But why the difference?
Van Ameringen suggests it boils down to how these substances interact with the brain. Cannabinoids activate CB1 receptors, which regulate symptoms like compulsions and anxiety, but don't provide lasting relief. Psilocybin, however, can reduce connectivity in the brain's default mode network, which is linked to self-referential thinking and rumination, both key aspects of OCD.
But here's where it gets controversial: The methodology of studies might also play a role. Dr. Mohamed Sherif, a psychiatrist, points out that psychedelic trials often encourage patients to view their experience as a therapeutic "journey," which isn't always the case in cannabinoid studies.
Dr. Terrence Ching, a clinical psychologist, adds another layer to the discussion. He wonders if the way people use cannabis versus psilocybin explains the difference. While cannabis is often used for temporary relief, psilocybin can facilitate lasting changes in the brain and in how patients perceive their OCD.
Ching's clinical trial, included in Van Ameringen's review, showed that psilocybin was effective for OCD symptoms compared to a placebo. During the trial, patients received psilocybin or a placebo and were guided by facilitators who offered minimal direction, focusing on open-ended questions. The protocol included strict ethical guidelines, such as limiting physical touch.
Ching believes the trial revealed more about the nature of OCD, both for clinicians and participants. Psilocybin is known for inducing "mystical experiences," but in OCD patients, these experiences are often partial, with patients "pumping the brakes" due to their need for control. Clinicians must remain non-directive and non-judgmental.
During the trial, patients gained insight into their need for control, realizing that life is full of the unknown. Ching is hopeful about psychedelic medications but acknowledges several obstacles. Psilocybin remains an illegal substance in the US, requiring researchers to take extra steps. Researchers also face the challenge of "functional unblinding" because participants can often guess whether they received psilocybin or a placebo, which could skew their perception of symptoms.
Ching emphasizes the need to treat psychedelics seriously, like any other medication, and to investigate them in a controlled, rigorous, and ethical way, while honoring traditional Indigenous users.
What are your thoughts? Do you think psychedelics hold the key to treating OCD, or are there other factors at play? Share your perspective in the comments below!
